Central Nervous System (CNS) Cancer - Pipeline Review, H2 2012

Description: Central Nervous System (CNS) Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct's, 'Central Nervous System (CNS) Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Central Nervous System (CNS) Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Central Nervous System (CNS) Cancer. Central Nervous System (CNS) Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Central Nervous System (CNS) Cancer.
- A review of the Central Nervous System (CNS) Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Central Nervous System (CNS) Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Central Nervous System (CNS) Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Central Nervous System (CNS) Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

2
List of Tables 8
List of Figures 14
Introduction 15
REPORT COVERAGE 15
Central Nervous System (CNS) Cancer Overview 16
Therapeutics Development 17
An Overview of Pipeline Products for Central Nervous System (CNS) Cancer 17
Central Nervous System (CNS) Cancer Therapeutics under Development by Companies 19
Central Nervous System (CNS) Cancer Therapeutics under Investigation by Universities/Institutes 30
Late Stage Products 43
Comparative Analysis 43
Mid Clinical Stage Products 44
Comparative Analysis 44
Early Clinical Stage Products 45
Comparative Analysis 45
Discovery and Pre-Clinical Stage Products 46
Comparative Analysis 46
Central Nervous System (CNS) Cancer Therapeutics – Products under Development by Companies 47
Central Nervous System (CNS) Cancer Therapeutics – Products under Investigation by Universities/Institutes 60
Companies Involved in Central Nervous System (CNS) Cancer Therapeutics Development 102
Genzyme Corporation 102
Boehringer Ingelheim GmbH 103
F. Hoffmann-La Roche Ltd. 104
Vical Incorporated 105
United Therapeutics Corporation 106
Amgen Inc. 107
Sanofi-Aventis 108
AstraZeneca PLC 109
Eli Lilly and Company 110
Viralytics Ltd. 111
GlaxoSmithKline plc 112
Genentech, Inc. 113
Nektar Therapeutics 114
Antigenics, Inc. 115
MedImmune LLC 116
Merck & Co., Inc. 117
Lentigen Corporation 118
Sangamo BioSciences, Inc. 119
Gamida Cell Ltd. 120
Plexxikon Inc. 121
YM BioSciences Inc. 122
Light Sciences Oncology, Inc. 123
Celltrion, Inc. 124
Ark Therapeutics Group plc 125
Histogen, Inc. 126
Novartis AG 127
Actelion Ltd 128
Dong-A Pharmaceutical Co., Ltd. 129
Eisai Co., Ltd. 130
Nippon Shinyaku Co., Ltd. 131
OSI Pharmaceuticals, Inc. 132
Pfizer Inc. 133
Teva Pharmaceutical Industries Limited 134
Cell Therapeutics, Inc. 135
Enzon Pharmaceuticals, Inc. 136
Exelixis, Inc. 137
Aduro BioTech 138
Alfacell Corporation 139
Merck KGaA 140
Advaxis, Inc. 141
GW Pharmaceuticals plc 142
Celldex Therapeutics, Inc. 143
AEterna Zentaris Inc. 144
Neuralstem, Inc. 145
ImmunoCellular Therapeutics, Ltd. 146
Lixte Biotechnology Holdings, Inc. 147
Bionomics Limited 148
Molecular Insight Pharmaceuticals, Inc. 149
Northwest Biotherapeutics, Inc. 150
Cleveland BioLabs, Inc. 151
Oncolytics Biotech Inc. 152
Oncothyreon Inc 153
Peregrine Pharmaceuticals, Inc. 154
Critical Outcome Technologies Inc. 155
Pharmacyclics, Inc. 156
PhytoMedical Technologies, Inc. 157
Transgene SA 158
Prana Biotechnology Limited 159
Diamyd Medical AB 160
Threshold Pharmaceuticals, Inc. 161
Natco Pharma Limited 162
Sareum Holdings plc 163
Proximagen Neuroscience plc. 164
e-Therapeutics plc 165
Rexahn Pharmaceuticals, Inc. 166
MabVax Therapeutics, Inc. 167
Spectrum Pharmaceuticals, Inc. 168
Antisense Pharma GmbH 169
INSYS Therapeutics, Inc. 170
Bionucleon Srl 171
Ambit Biosciences Corporation 172
Immupharma Plc 173
Adnexus Therapeutics, Inc. 174
immatics biotechnologies GmbH 175
Advantagene, Inc. 176
Apogenix GmbH 177
BioNumerik Pharmaceuticals, Inc. 178
Indena S.p.A. 179
AngioChem Inc. 180
Ascenta Therapeutics, Inc. 181
Oncoscience AG 182
Hawthorn Pharmaceuticals, Inc. 183
Diffusion Pharmaceuticals LLC 184
MacroGenics, Inc. 185
Pervasis Therapeutics, Inc. 186
Fina Biotech 187
Arno Therapeutics, Inc. 188
Merrimack Pharmaceuticals, Inc. 189
Nobelpharma Co., Ltd. 190
Neotropix, Inc. 191
PTC Therapeutics, Inc. 192
Deciphera Pharmaceuticals, LLC 193
Vascular Biogenics Ltd. 194
Burzynski Research Institute, Inc. 195
Jennerex Biotherapeutics, Inc. 196
Stemline Therapeutics, Inc. 197
BioCancell Therapeutics, Inc. 198
Axelar AB 199
Advenchen Laboratories, LLC 200
Viral Genetics, Inc. 201
Myriad Pharmaceuticals, Inc. 202
NOXXON Pharma AG 203
OncoMune, LLC 204
APEIRON Biologics AG 205
ChemoCentryx, Inc. 206
Cellceutix Corporation 207
TVAX Biomedical, LLC 208
Sirnaomics, Inc. 209
Kinex Pharmaceuticals, LLC 210
to-BBB technologies BV 211
Lipopharma 212
ZGene A/S 213
Kringle Pharma, Inc. 214
Nexgenix Pharmaceuticals, LLC 215
Central Nervous System (CNS) Cancer – Therapeutics Assessment 231
Assessment by Monotherapy Products 231
Assessment by Combination Products 232
Assessment by Route of Administration 233
Assessment by Molecule Type 235
Drug Profiles 238
enzastaurin hydrochloride - Drug Profile 238
cediranib maleate - Drug Profile 240
rindopepimut - Drug Profile 242
bevacizumab - Drug Profile 243
cilengitide - Drug Profile 245
DCVax-L - Drug Profile 247
Antineoplaston A-10 + Antineoplaston AS2-1 - Drug Profile 249
cintredekin besudotox - Drug Profile 251
trabedersen - Drug Profile 253
corticorelin acetate - Drug Profile 255
Recentin + Lomustine - Drug Profile 257
Carboplatin + Etoposide + Melphalan + Autologous Stem Cell Transplantation - Drug Profile 258
Radiation Therapy + Temozolomide - Drug Profile 259
Temozolomide + Radiation Therapy + Bevacizumab - Drug Profile 261
Bevacizumab + Temozolomide + Radiation Therapy - Drug Profile 263
Octreotide acetate + Recombinant interferon alfa-2b - Drug Profile 265
Bevacizumab + Temozolomide - Drug Profile 267
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Methotrexate + Temozolomide + Thiotepa + Vincristine + Stem cell transplantation + Radiation Therapy - Drug Profile 269
Temozolomide - Drug Profile 272
Temozolomide + Etoposide - Drug Profile 274
Carboplatin + Cyclophosphamide + Etoposide + Vincristine - Drug Profile 275
Carboplatin + Cisplatin + Cyclophosphamide + Dactinomycin + Doxorubicin + Etoposide + Vincristine - Drug Profile 277
Cisplatin + Cyclophosphamide + Vincristine Sulfate + Radiation Therapy + Autologous Stem Cell Transplantation - Drug Profile 279
Carboplatin + Cyclophosphamide + Etoposide + Irinotecan + Temozolomide + Vincristine - Drug Profile 282
Temozolomide + Radiation Therapy - Drug Profile 284
Temozolomide + Radiation Therapy - Drug Profile 286
Cilengitide + Temozolomide + Radiation Therapy - Drug Profile 287
Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Leucovorin + Methotrexate + Thiotepa + Vincristine + Peripheral Stem Cell Transplantation - Drug Profile 289
Lomustine + Procarbazine + Vincristine + Radiation Therapy - Drug Profile 291
Temozolomide + Radiation Therapy - Drug Profile 293
porfimer sodium - Drug Profile 295
Cyclophosphamide + Total-Body Irradiation + Autologous Stem Cell Transplantation - Drug Profile 296
Busulfan + Cyclophosphamide + Autologous Stem Cell Transplantation - Drug Profile 297
Carmustine + O6-Benzylguanine + Radiation Therapy - Drug Profile 298
O6-benzylguanine + Carmustine + Radiation therapy - Drug Profile 300
Trinity Multipotent Stem Cells - Drug Profile 302
Carboplatin + Cisplatin - Drug Profile 303
Theracim + Radiation Therapy - Drug Profile 304
Avastin + Temozolomide - Drug Profile 305
Temozolomide - Drug Profile 307
Temozolomide - Drug Profile 308
Temozolomide + Radiation Therapy - Drug Profile 309
Temozolomide + Lomustine - Drug Profile 310
Temozolomide - Drug Profile 311
Carboplatin + Cyclophosphamide + Etoposide + Leucovorin + Methotrexate + Vincristine - Drug Profile 312
Nimotuzumab + Temozolomide - Drug Profile 314
erlotinib hydrochloride - Drug Profile 315
Radiation Therapy + Procarbazine + ACNU - Drug Profile 317
Radiation Therapy + ACNU - Drug Profile 318
Cyclophosphamide + Vincristine - Drug Profile 319
Temozolomide + Etoposide + Trofosfamid - Drug Profile 320
Thioguanine + Procarbazine + Lomustine + Vincristine - Drug Profile 322
Cisplatin + Lomustine + Vincristine - Drug Profile 324
Carboplatin + Temozolomide + Thiotapec + Vincristine + Stem Cell Transplantation + Radiation Therapy - Drug Profile 325
Carboplatin + Etoposide + Vincristine + Radiation Therapy - Drug Profile 327
Cyclophosphamide + Etoposide + Vincristine + Radiation Therapy - Drug Profile 329
Carboplatin + Etoposide + Melphalan + CD133+ Selected Autologous Stem Cell Transplantation - Drug Profile 331
Carboplatin + Cyclophosphamide + Etoposide + Vincristine + Doxorubicin + Cisplatin - Drug Profile 333
Cisplatin + Lomustine + Vincristine Sulfate + Radiation Therapy - Drug Profile 335
temozolomide - Drug Profile 337
Procarbazine + Lomustine + Vincristine - Drug Profile 339
temozolomide - Drug Profile 340
Cisplatin + Lomustine + Vincristine Sulfate - Drug Profile 341
Filgrastim + Monoclonal Antibody Ch14.18 + Busulfan + Carboplatin + Cyclophosphamide + Etoposide +
Isotretinoin + Melphalan + Vincristine Sulfate - Drug Profile 343
G-CSF + Carboplatin + Cisplatin + Cyclophosphamide + Isotretinoin + Vincristine - Drug Profile 346
G-CSF + Carboplatin + Cisplatin + Cyclophosphamide + Vincristine + Radiation Therapy - Drug Profile 348
G-CSF + Cisplatin + Cyclophosphamide + Isotretinoin + Vincristine + Radiation Therapy - Drug Profile 350
Cytoscan + Melphalan + Autologous Stem Cell Transplantation - Drug Profile 351
Carboplatinum + VP-16 + Thiotapec + Autologous Stem Cell Transplantation - Drug Profile 352
Temodal + Radiation Therapy - Drug Profile 354
ch-14.18 - Drug Profile 355
temozolomide - Drug Profile 356
Atengenal + Astugenal - Drug Profile 357
Rituximab + Methotrexate + Teniposide + BCNU + Prednisolone + ARA-C + Radiation Therapy - Drug Profile 359
Cisplatin + Cyclophosphamide + Etoposide + Vincristine - Drug Profile 361
Cyclophosphamide + Prednisone + Gammaglobulin Therapy - Drug Profile 363
Lomustine + Procarbazine + Vincristine - Drug Profile 365
APN-311 - Drug Profile 367
Temodol + Radiotherapy - Drug Profile 369
Eir-060 - Drug Profile 370
Eir-080 - Drug Profile 371
Central Nervous System (CNS) Cancer Therapeutics – Drug Profile Updates 372
Central Nervous System (CNS) Cancer Therapeutics – Discontinued Products 382
Central Nervous System (CNS) Cancer Therapeutics - Dormant Products 391
Central Nervous System (CNS) Cancer – Product Development Milestones 442
Featured News & Press Releases 442
Appendix 449
Methodology 449
Coverage 449
Secondary Research 449
Primary Research 449
Expert Panel Validation 449
Contact Us 450
Disclaimer 450

List of Tables
Number of Products Under Development for Central Nervous System (CNS) Cancer, H2 2012 23
Products under Development for Central Nervous System (CNS) Cancer – Comparative Analysis, H2 2012 24
Number of Products under Development by Companies, H2 2012 26
Number of Products under Development by Companies, H2 2012 (Contd..1) 27
Number of Products under Investigation by Universities/Institutes, H2 2012 37
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 38
Comparative Analysis by Late Stage Development, H2 2012 49
Comparative Analysis by Mid Clinical Stage Development, H2 2012 50
Comparative Analysis by Early Clinical Stage Development, H2 2012 51
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 52
Products under Development by Companies, H2 2012 53
Products under Development by Companies, H2 2012 (Contd..1) 54
Products under Investigation by Universities/Institutes, H2 2012 66
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 67
Genzyme Corporation, H2 2012 108
Boehringer Ingelheim GmbH, H2 2012 109
F. Hoffmann-La Roche Ltd., H2 2012 110
Vical Incorporated, H2 2012 111
United Therapeutics Corporation, H2 2012 112
Amgen Inc., H2 2012 113
Sanofi-Aventis, H2 2012 114
AstraZeneca PLC, H2 2012 115
Eli Lilly and Company, H2 2012 116
Viralytics Ltd., H2 2012 117
GlaxoSmithKline plc, H2 2012 118
Genentech, Inc., H2 2012 119
Nektar Therapeutics, H2 2012 120
Antigenics, Inc., H2 2012 121
MedImmune LLC, H2 2012 122
Merck & Co., Inc., H2 2012 123
Lentigen Corporation, H2 2012 124
Sangamo BioSciences, Inc., H2 2012 125
Gamida Cell Ltd., H2 2012 126
Plexxikon Inc., H2 2012 127
YM BioSciences Inc., H2 2012 128
Light Sciences Oncology, Inc., H2 2012 129
Celltrion, Inc., H2 2012 130
Ark Therapeutics Group plc, H2 2012 131
Histogen, Inc., H2 2012 132
Novartis AG, H2 2012 133
Actelion Ltd, H2 2012 134
Dong-A Pharmaceutical Co., Ltd., H2 2012 135
Eisai Co., Ltd., H2 2012 136
Nippon Shinyaku Co., Ltd., H2 2012 137
OSI Pharmaceuticals, Inc., H2 2012 138
Pfizer Inc., H2 2012 139
Teva Pharmaceutical Industries Limited, H2 2012 140
Cell Therapeutics, Inc., H2 2012 141
Enzon Pharmaceuticals, Inc., H2 2012 142
Exelixis, Inc., H2 2012 143
Aduro BioTech, H2 2012 144
Alfacell Corporation, H2 2012 145
Merck KGaA, H2 2012 146
Advaxis, Inc., H2 2012 147
GW Pharmaceuticals plc, H2 2012 148
CellDex Therapeutics, Inc., H2 2012 149
AETerna Zentaris Inc., H2 2012 150
Neuralstem, Inc., H2 2012 151
ImmunoCellular Therapeutics, Ltd., H2 2012 152
Lixte Biotechnology Holdings, Inc., H2 2012 153
Bionomics Limited, H2 2012 154
Molecular Insight Pharmaceuticals, Inc., H2 2012 155
Northwest Biotherapeutics, Inc., H2 2012 156
Cleveland BioLabs, Inc., H2 2012 157
Oncolytics Biotech Inc., H2 2012 158
Oncothyreon Inc, H2 2012 159
Peregrine Pharmaceuticals, Inc., H2 2012 160
Critical Outcome Technologies Inc., H2 2012 161
Pharmacyclics, Inc., H2 2012 162
PhytoMedical Technologies, Inc., H2 2012 163
Transgene SA, H2 2012 164
Prana Biotechnology Limited, H2 2012 165
Diamyd Medical AB, H2 2012 166
Threshold Pharmaceuticals, Inc., H2 2012 167
Natco Pharma Limited, H2 2012 168
Sareum Holdings plc, H2 2012 169
Proximagen Neuroscience plc, H2 2012 170
e-Therapeutics plc, H2 2012 171
Rexahn Pharmaceuticals, Inc., H2 2012 172
MabVax Therapeutics, Inc., H2 2012 173
Spectrum Pharmaceuticals, Inc., H2 2012 174
Antisense Pharma GmbH, H2 2012 175
INSYS Therapeutics, Inc., H2 2012 176
Bionucleon Srl, H2 2012 177
Ambit Biosciences Corporation, H2 2012 178
Immupharma Plc, H2 2012 179
Adnexus Therapeutics, Inc., H2 2012 180
immatics biotechnologies GmbH, H2 2012 181
Advantagene, Inc., H2 2012 182
Apogenix GmbH, H2 2012 183
BioNumerik Pharmaceuticals, Inc., H2 2012 184
Indena S.p.A., H2 2012 185
AngioChem Inc., H2 2012 186
Ascenta Therapeutics, Inc., H2 2012 187
Oncoscience AG, H2 2012 188
Hawthorn Pharmaceuticals, Inc., H2 2012 189
Diffusion Pharmaceuticals LLC, H2 2012 190
MacroGenics, Inc., H2 2012 191
Pervasis Therapeutics, Inc., H2 2012 192
Fina Biotech, H2 2012 193
Arno Therapeutics, Inc., H2 2012 194
Merrimack Pharmaceuticals, Inc., H2 2012 195
Nobelpharma Co., Ltd., H2 2012 196
Neotropix, Inc., H2 2012 197
PTC Therapeutics, Inc., H2 2012 198

List of Figures
Number of Products under Development for Central Nervous System (CNS) Cancer, H2 2012 23
Products under Development for Central Nervous System (CNS) Cancer – Comparative Analysis, H2 2012 24
Products under Development by Companies, H2 2012 25
Products under Investigation by Universities/Institutes, H2 2012 36
Late Stage Products, H2 2012 49
Mid Clinical Stage Products, H2 2012 50
Early Clinical Stage Products, H2 2012 51
Discovery and Pre-Clinical Stage Products, H2 2012 52
Assessment by Monotherapy Products, H2 2012 237
Assessment by Combination Products, H2 2012 238
Assessment by Route of Administration, H2 2012 239
Assessment by Stage and Route of Administration, H2 2012 240
Assessment by Molecule Type, H2 2012 241
Assessment by Stage and Molecule Type, H2 2012 242

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

| Product Name: | Central Nervous System (CNS) Cancer - Pipeline Review, H2 2012 |
| Web Address:  | http://www.researchandmarkets.com/reports/2245254/ |
| Office Code:  | SCD2ST23 |

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2500</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - Site License:</td>
<td>USD 5000</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 7500</td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
</tbody>
</table>
| Bank Address   | Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World